Pattern of Pro-Angiogenic Serum Placental Growth Factor in Gestational Hypertensive Women

Authors

  • Qurat ul Ain Department of Physiology, Sharif Medical and Dental College Lahore, Pakistan.
  • Sana Qanber Abbasi Department of Physiology, Sharif Medical and Dental College Lahore, Pakistan.
  • Rabia Sattar Department of Physiology, Sharif Medical and Dental College Lahore, Pakistan.
  • Ghazal Mansoor Department of Physiology, Sharif Medical and Dental College Lahore, Pakistan.
  • Ejaz Ahmed Department of Physiology, Sharif Medical and Dental College Lahore, Pakistan.
  • Noor ul Ain Department of Food Sciences and Technology, Gomal University D.I. Khan, Pakistan.
  • Sana Ashiq Center for Applied Molecular Biology, University of Punjab, Lahore, Pakistan. https://orcid.org/0000-0003-0418-4022

DOI:

https://doi.org/10.36570/jduhs.2020.2.925

Keywords:

PLGF, Angiogenesis, Gestational hypertension, Placentation

Abstract

Objective: The aim of this study was to investigate maternal serum levels of an angiogenic factor called Placental Growth Factor (PLGF) at different ages of pregnancy in gestational hypertensive women residing in Raiwind Lahore, Pakistan.

Methods: The analytical cross-sectional study was conducted at the Department of Obstetrics and Gynecology Sharif Medical City Hospital, Lahore from January 2015 - April 2015. Serum levels of PLGF were measured and compared between 22 control normotensive subjects (Group A) and 18 gestational hypertensive (Group B). Moreover, comparison was also made among different gestational weeks groups (I, II and III).

Results: Serum PLGF levels were raised in gestational hypertensive (Group B) compare to normotensive (Group A) [366 (185-695) vs. 156 (132-319) ng/L], (P= 0.024). Serum PLGF levels were 156 (132-319) in gestational hypertensive individuals and 366 (185-695) ng/L in normotensive individuals. Serum levels PLGF of 18 -28 (I), 29-35 gestational weeks (II) were raised [425 (197-452) vs. 163 (91-332)], [546 (309-1519) vs. 137 (86-147)]. While in last 36- 40 weeks group (III) levels were decreased [216 (136-881) vs. 315 (185-612)] in comparison of normotensive subjects.

Conclusion: It is concluded from this research that placental–derived angiogenic biomarker PLGF plays a significant role in gestational hypertension. The pattern of the PLGF marker in various intervals of pregnancy may provide information for the management of hypertension in pregnancy.

Downloads

Download data is not yet available.

References

1. Braunthal S, Brateanu A. Hypertension in pregnancy: pathophysiology and treatment. SAGE Open Med 2019; 7:1-15. DOI: doi.org/10.1177/2050312119843700
2. Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol 2013; 25:124-32.DOI: 10.1097/GCO.0b013e32835e0ef5
3. Jurado S, Saraiva K, Marceliano C, Souza V, Vieira I. Maternal and fetal complications due to decreased nitric oxide synthesis during gestation. Complications of Pregnancy. 2019. DOI: doi:10.5772/intechopen.85383
4. Sukumar N, Dallosso H, Saravanan P, Yates T, Telling C, Shorthose K, et al. Baby Steps–a structured group education programme with accompanying mobile web application designed to promote physical activity in women with a history of gestational diabetes: study protocol for a randomised controlled trial. Trials 2018; 19:682. DOI: doi.org/10.1186/s13063-018-3067-8
5. Rehman O, Din SU, Siddiqui M A, Rehman S. Incidence of women having pregnancy induced hypertension in Karachi. Pak J Pharmacol 2003; 20:5-8.
6. Wen YH, Yang HI, Chou HC, Chen CY, Hsieh WS, Tsou KI, et al. Association of maternal preeclampsia with neonatal respiratory distress syndrome in very-Low-birth-weight infants. Sci Rep 2019; 9:1-8. DOI: doi.org/10.1038/s41598-019-49561-8
7. Rather RH, Nazir SB, Khan SM. Risk factors of pregna- ncy induced hypertension in block Hazratbal of district Srinagar, Jammu & Kashmir-a prospective longitudinal study. Int Res J Public Health 2019; 3:27.
8. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018; 72:24-43. DOI: doi.org/10.1161/HYPERTENSIONAHA.117.10803
9. Byrne TJ. New Pharmacologic therapy for hypertens-ion in pregnancy. J Hypertens Manag 2019; 5:041.
10. Farrukh S, Baig S, Hussain R, Shahid A, Khan ST. Telo-mere reprogramming during fetal life in low socioeconomic mothers. Egypt J Med Hum Genet 2019; 20:1-10. DOI: doi.org/10.1186/s43042-019-0007-4
11. Marwan AI, Shabeka U, Dobrinskikh E. Suggested mechanisms of tracheal occlusion mediated accelerated fetal lung growth: a case for heterogeneous topological zones. Front Pediatr 2018; 5:295. DOI:doi.org/10.3389/fped.2017.00295
12. Beukers F, Aarnoudse‐Moens CS, van Weissenbruch MM, Ganzevoort W, van Goudoever JB, van Wassenaer‐Leemhuis AG. Maternal psychological distress after severe pregnancy hypertension was associated with increased child behavioural problems at the age of 12. Acta Paediatr 2019; 108:1061-6.
DOI: doi.org/10.1111/apa.14676
13. Umapathy A, Chamley LW, James JL. Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies. Angiogenesis 2020; 23:105-17. DOI: doi.org/10.1007/s10456-019-09694-w
14. Milosevic-Stevanovic J, Krstic M, Radovic-Janosevic D, Stefanovic M, Antic V, Djordjevic I. Preeclampsia with and without intrauterine growth restriction–two pathogenetically different entities? Hypertens Pregna-ncy 2016; 35:573-82. DOI: doi.org/10.1080/10641955.2016.1212872
15. Anto EO. Angiogenic factors and oxidative stress biomarkers in gestational hypertension and preeclampsia (Doctoral dissertation). 2018. Available at: http://ir.knust.edu.gh/handle/123456789/8002
16. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M. Zeisler H, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206:58. DOI: doi.org/10.1016/j.ajog.2011.07.037
17. Maynard SE, Crawford SL, Bathgate S, Yan J, Robidoux L, Moore M, et al. Gestational angiogenic biomarker patterns in high risk preeclampsia groups. Am J Obstet Gynecol 2013; 209:53-9. DOI: doi.org/10.1016/j.ajog.2013.03.017
18. Costa RA, Hoshida MS, Alves EA, Zugaib M, Francisco RP. Preeclampsia and superimposed preeclampsia: the same disease? The role of angiogenic biomarkers. Hypertens Pregnancy 2016; 35:139-49. DOI: doi.org/10.3109/10641955.2015.1115063
19. Eastwood KA, Hunter AJ, Patterson CC, McCance DR, Young I, Holmes VA. Annals express: the role of biomarkers in predicting pre-eclampsia in high-risk women. Ann Clin Biochem 2019; 57:128-37. DOI: doi.org/10.1177/0004563219894022
20. Rana S, Salahuddin S, Mueller A, Berg AH, Thadhani RI, Karumanchi SA. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens 2018; 13:100-6.
DOI:doi.org/10.1016/j.preghy.2018.05.008
21. Zhao M, Zhu Z, Liu C, Zhang Z. Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia: a systematic review and meta-analysis. Arch Gynecol Obstet 2017; 295:1079-87. DOI: doi.org/10.1007/s00404-017-4302-3
22. Veisani Y, Jenabi E, Delpisheh A, Khazaei S. Angiogenic factors and the risk of preeclampsia: a systematic review and meta-analysis. Int J Reprod Biomed 2019;17:1-10. DOI: 10.18502/ijrm.v17i1.3815
23. Khalil A, Muttukrishna S, Harrington K, Jauniaux E. Eff-ect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One 2008; 3.
DOI: doi.org/10.1371/journal.pone.0002766
24. Shah DA, Khalil RA. Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia. Biochem Pharmacol 2015; 95:211-26. DOI: doi.org/10.1016/j.bcp.2015.04.012

Downloads

Published

2020-08-30

How to Cite

Ain, Q. ul, Abbasi, S. Q., Sattar, R., Mansoor, G., Ahmed, E., Ain, N. ul, & Ashiq, S. (2020). Pattern of Pro-Angiogenic Serum Placental Growth Factor in Gestational Hypertensive Women. Journal of the Dow University of Health Sciences (JDUHS), 14(2), 72–76. https://doi.org/10.36570/jduhs.2020.2.925

Issue

Vol. 14 No. 2

Section

Original Articles

License

Copyright (c) 2020 Qurat ul Ain, Sana Qanber Abbasi, Rabia Sattar, Ghazal Mansoor, Ejaz Ahmed, Noor ul Ain, Sana Ashiq

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Articles published in the Journal of Dow University of Health Sciences are distributed under the terms of the Creative Commons Attribution Non-Commercial License https://creativecommons.org/ licenses/by-nc/4.0/. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal.